www.fdanews.com/articles/85199-eli-lilly-starts-trial-of-enzastaurin
ELI LILLY STARTS TRIAL OF ENZASTAURIN
March 10, 2006
Eli Lilly will treat nearly 400
patients with glioblastoma multiforme with either enzastaurin or the common chemotherapeutic
agent CeeNU in a Phase III trial that the company has dubbed STEERING (for Study
Evaluating Enzastaurin in Recurrent Glioblastoma).
Enzastaurin, which
has been granted orphan-drug status by the FDA, is an oral serine-threonine kinase
inhibitor. The company is studying whether enzastaurin could be useful in treating
other cancers, including non-Hodgkin's lymphoma, colorectal cancer and non-small
cell lung cancer.